• Journal of the Korea Society of Computer and Information
• /
• v.10 no.6 s.38
• /
• pp.337-344
• /
• 2005

In order to Perform a PSA. it requires a large number of data for various fields. Therefore, the effective management of the data is essential to perform and review a PSA and to maintain the quality of a PSA. Korea Atomic Energy Research Institute (KAERI) is developing a PSA information management system (AIMS: Advanced Information Management System for PSA) which enhances the accessibility to PSA information for all PSA related activities. The AIMS is a database system that stores all references and links to the information used for the PSA analysis. The AIMS consists of a database, information browsing modules and a PSA model manager. This Paper describes how we implemented such a database centered application in the view of two areas, database design and data (document) service.

• The Journal of the Korean life insurance medical association
• /
• v.29 no.1
• /
• pp.16-21
• /
• 2010

The measurement of prostate specific antigen (PSA) in screening for prostate cancer is recently performed as a routine check-up in clinical medicine and insurance medicine. Several factors may affect serum PSA levels. As prostate size increases with increasing age, the PSA concentration also rises. Increasing body mass index (BMI) is associated with a lower mean PSA concentration. Inhibitors of 5-alpha-reductase such as finasteride and dutasteride produce a 50 percent or greater decrease in serum PSA during the first three months of therapy, which persists as long as the drug is continued. Men who are regularly taking non-steroidal antiinflammatory drugs (NSAIDs) or acetaminophen have lower PSA levels. Emerging concepts regarding PSA testing that may help refine the interpretation of an elevated concentration include: PSA density, PSA velocity, and Free versus complexed or bound PSA. With many insurance companies, PSA level has become part of a standard battery of blood tests, along with HIV, cholesterol, liver enzymes, and other predictors of premature death. But, there is no clear proof of benefit, so we have to monitor the value of PSA test as a prostate cancer screening test in insurance medicine.

• Journal of Ginseng Research
• /
• v.2 no.1
• /
• pp.17-33
• /
• 1977

Panax Saponin A(PSA) , one of dammarane glycosides of Korean ginseng, was labeled with $^{3}H$ or $^{14}C$ by our Previously reported Procedures of organic synthesis. Tracer studies with $^{3}H$-PSA in wino yielded the following results: 1). Oral and intraperitoneal administration of $^{3}H$-PSA resulted in the rapid appearance and prolonged retention of $^{3}H$-PSA in all organs such as liver, brain, bone marrow and spleen of mice. 2). The amount pi cellular intake of $^{3}H$-PSA was shown to have a certain level of saturation ranging from 0.4mg to 0. 7mg Per 20gm body weight of mice. Administration of $^{3}H$-PSA within the dosage of the saturation point did net give urinary excretion of 3H-PSA. On the contrary, excessive administration of $^{3}H$-PSA resulted in rapid excretion of the substance in the urine of mice.

• Radiation Oncology Journal
• /
• v.17 no.2
• /
• pp.136-140
• /
• 1999

Purpose : Prostate specific antigen (PSA) is a useful tumor marker, which is widely used as a diagnostic index and predictor of both treatment and follow-up result in prostate cancer. A prospective analysis was carried out to obtain the period of PSA normalization and the half life of PSA and to analyze the factors influencing the period of PSA normalization. The PSA level was checked before and serially after radical radiotherapy. Materials and Method : Twen쇼 patients with clinically localized prostate cancer who underwent radical external beam radiotherapy were enrolled in this study. Accrual period was from April 1993 to May 1998. Median follow-up period was 20 months. Radiotherapy was given to whole pelvis followed by a boost to prostate. Dose range for the whole pelvis was from 45 Gy to 50 Gy and boost dose to prostate, from 14 Gy to 20 Gy. The post-irradiation PSA normal value was under 3.0 ng/ml. The physical examination and serum PSA level evaluation were performed at 3 month interval in the first one year, and then at every 4 to 6 months. Results : PSA value was normalized in nineteen patients (95%) within 12 months. The mean period of PSA normalization was 5.3 (${\pm}$2.7) months. The half life of PSA Of the nonfailing patients was 2.1 (${\pm}$0.9) month. The nadir PSA level Of the nonfailing Patients waS 0.8 (${\pm}$0.5) ng/ml. The period of PSA normalization had the positive correlation with pretreatment PSA level (R$^{2}$=0.468). The nadir PSA level had no definite positive correlation with the pretreatment PSA level (R$^{2}$=0.075). The half life of serum PSA level also had no definite correlation with pretreatment PSA level (R$^{2}$=0.029). Conclusion :The PSA level was mostly normalized within 8 months (85%). If it has not normalized within 12 months, we should consider the residual disease in prostate or distant metastasis. In 2 patients, the PSA level increased 6 months or 20 months before clinical disease was detected. So the serum PSA level can be used as early diagnostic indicator of treatment failure.

• Nuclear Engineering and Technology
• /
• v.50 no.8
• /
• pp.1255-1265
• /
• 2018

The need for a PSA (Probabilistic Safety Assessment) for a multi-unit at a site is growing after the Fukushima accident. Many countries have been studying issues regarding a multi-unit PSA. One of these issues is the problem of many combinations of accident sequences in a multi-unit PSA. This paper deals with the methodology and software to quantify a PSA scenarios for a multi-unit site. Two approaches are developed to quantify a multi-unit PSA. One is to use a minimal cut set approach, and the other is to use a Monte Carlo approach.

• Nuclear Engineering and Technology
• /
• v.36 no.1
• /
• pp.83-103
• /
• 2004

The methodological framework of the Level 2 PSA appears to be currently standardized in a formalized fashion, but there have been different opinions on the way the sources of uncertainty are characterized and treated. This is primarily because the Level 2 PSA deals with complex phenomenological processes that are deterministic in nature rather than random processes, and there are no probabilistic models characterizing them clearly. As a result, the probabilistic quantification of the Level 2 PSA CET / APET is often subjected to two sources of uncertainty: (a) incomplete modeling of accident pathways or different predictions for the behavior of phenomenological events and (b) expert-to-expert variation in estimating the occurrence probability of phenomenological events. While a clear definition of the two sources of uncertainty involved in the Level 2 PSA makes it possible to treat an uncertainty in a consistent manner, careless application of these different sources of uncertainty may produce different conclusions in the decision-making process. The primary purpose of this paper is to characterize typical sources of uncertainty that would often be addressed in the Level 2 PSA and to provide a formal guidance for quantifying their impacts on the PSA Level 2 risk results. An additional purpose of this paper is to give a formal approach on how to combine random uncertainties addressed in the Level 1 PSA with subjectivistic uncertainties addressed in the Level 2 PSA.

• Biomedical Science Letters
• /
• v.3 no.2
• /
• pp.107-114
• /
• 1997

Recent reports indicate that the clinical usefulness of prostate specific antigen (PSA), particulary in the differentiation of benign prostate hyperplasia from prostate cancer, can be improved by measuring the amount of free PSA in serum. Measuring free PSA is especially useful in attempts to improve diagnositc performance of PSA in the diagnostic gray zone of total PSA. The objective of this study was to develop free PSA assay kit using sandwich microplate enzyme immunoassay format. We chose a test format with polyclonal anti-PSA antibodies coated on the wells and monoclonal anti-free PSA antibodies for quantification to gain higher test sensitivity. We adpoted 10 uL of specimen and 2 hours of first incubation time with detecting antibody for free PSA EIA format using microplate. The within-day and between-day precision (%CV) in the high and low concentration ranges were below 4%. The correlation coefficient between in-house free PSA assay and commercial assay kit was r=0.9965 (slope=0.0984, y intercept=0.0173, N=27). No hook effect was found by 40 ng/mL and correlation coefficient (r) value of the fitted linear regression was over 0.995. The recovery tests were in the range of 98.9∼104.1％ for free PSA. In conclusion, in-house free PSA enzyme immune assay is cost effective, simple and rapid and could be useful for the prognosis after theraphy as well as for the differential diagnosis between prostate cancer and benign prostate hyperplasia.

• Korean Journal of Microbiology
• /
• v.50 no.3
• /
• pp.245-248
• /
• 2014

Pseudomonas syringae pv. actinidiae is the causal agent of bacterial canker in kiwifruit (genus Actinidia). Multilocus sequence analysis of seven housekeeping and 11 type III effector genes differentiated the virulent P. syringae pv. actinidiae isolates worldwide into three groups designated as Psa1-Psa3. In this work, a total of 12 P. syringae pv. Actinidiae strains, including three Psa1, three Psa2, three Psa3 strains isolated from Korea and three Psa3 strains from Italy, were compared based on their phenotypic properties. Strains with different geographic origins had unique growth patterns as demonstrated by growth rate at several temperatures; all tested strains exhibited maximum growth at temperatures below $22^{\circ}C$, while the growth of Psa3 strains was completely inhibited above $30^{\circ}C$. Psa3 strains isolated from Korea had longer lag phases than the Psa3 strains from Italy. The Psa2 strains were different from Psa1 and Psa3 strains in the API 20NE test, in which the Psa2 strains could not utilize potassium gluconate, capric acid and trisodium citrate. Psa3 strains isolated from Korea could hydrolyze esculin. The API ZYM test showed that ${\beta}$-glucosidase activity was detected only from Psa3 strains. The strains belonging to the three Psa groups differed with regard to their susceptibility to ampicillin, novobiocin, and oleandomycin.

• Fire Science and Engineering
• /
• v.17 no.1
• /
• pp.40-45
• /
• 2003

In this paper many vulnerable areas of the present fire PSA methodology were revealed to apply risk-informed fire protection to nuclear power plants. The results and insights from the fro PSA should be used as a part of a risk-informed decision making process rather than the complete technical basis for decision making. The degree of support and scope of applications is dependent on the accuracy and validity of the model used in the fire PSA. Accordingly; the usefulness of the fire PSA will increase as ongoing research and development efforts lead to improvements in the state of the art technology and as improvements in the implementation of the state of the art technology lead to more consistent results.

• Asian Pacific Journal of Cancer Prevention
• /
• v.16 no.13
• /
• pp.5261-5264
• /
• 2015

Purpose: To examine the effectiveness of serum free-to-total prostate specific antigen ratio (%fPSA) for the detection of prostate cancer (PCa) in men with different serum total PSA (tPSA) categories. Materials and Methods: From January 2010 to December 2013, a total of 225 patients with lower urinary tract symptoms (LUTS) underwent tPSA and %fPSA measurements. Histological examination with calculation of Gleason score and whole body bone scans were performed in identified cases of PCa. Results: PCa was diagnosed in 44 (19.6%) patients and the remaining 181 patients had benign prostate disease. PCa was detected in 5 (23.8%), 13 (8.7%) and 26 (47.3%) cases with tPSA level ranges ${\leq}4ng/ml$, 4 to 10 ng/ml and >10 ng/ml, respectively. The average Gleason score was $7.2{\pm}0.2$. Some 6 (13.6%) out of 44 PCa patients had bone metastases. The sensitivity was 80% and specificity was 81.3% at the cut-off %fPSA of 15% in PCa patients with a tPSA level below 4 ng/mL. A lower %fPSA was associated with PCa patients with Gleason score ${\geq}7$ than those with Gleason score ${\leq}6$ ($11.7{\pm}0.98$ vs. $16.5{\pm}2.25%$, P=0.029). No obvious relation of %fPSA to the incidence of bone metastasis was apparent in this study. Conclusions: The clinical application of %fPSA could help to discriminate PCa from benign prostate disease in men with a tPSA concentration below 4 ng/mL.